Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and investors who purchased Baxter common stock during this time may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by December 15, 2025, to represent other class members in the litigation [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter despite being notified of multiple device malfunctions and associated injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading, leading to investor damages when the true details became public [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 alone [5].

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious malfunctions and patient risks [3][4]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International and has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in the class action [1][5]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions such as underinfusion and overinfusion, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the Novum LVPs from service [3]. Impact on Stock Price - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price fell by 22.4%, closing at $21.76 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to safety concerns [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and fatalities linked to these defects [2]. - The company's attempts to address these issues through customer alerts were deemed insufficient, as design flaws persisted and continued to harm patients [2]. - There was an increased risk that customers would be advised to withdraw existing Novum LVPs from service, and Baxter might halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were alleged to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who experienced losses in Baxter International, Inc. during the specified period have until December 15, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects [1]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [1]. - There was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Insights - Pzena Investment Management LLC maintains a disciplined value investment strategy with a total portfolio value of $30.94 billion as of September 30, 2025, focusing on cyclical recoveries and normalized earnings power [1] Top Holdings - Magna International Inc. (MGA) leads the portfolio with a value of $1.92 billion, representing 6.19% of total assets, despite a slight reduction of 434,000 shares (–1.5%) [2] - Baxter International Inc. (BAX) follows with $1.31 billion (4.22%), having added 18 million shares (+45.9%), reflecting confidence in its restructuring and margin recovery [3] - Citigroup Inc. (C) is third at $1.27 billion (4.11%), with a reduction of approximately 1 million shares (–7.7%), indicating a belief in the bank's undervaluation [4] - Dollar General Corp. (DG) ranks fourth at $1.21 billion (3.9%), with a minor reduction of 171,000 shares (–1.5%), aligning with Pzena's preference for cash-generating franchises [5] - CVS Health Corp. (CVS) holds $1.19 billion (3.86%), having sold 901,000 shares (–5.4%), fitting the model of steady cash flows during market pessimism [6] Other Key Adjustments - Modest increases were noted in Cognizant Technology Solutions (CTSH) (+1.5%) and MetLife (MET) (+5.8%), while Wells Fargo (WFC) and Capital One (COF) were slightly trimmed, indicating fine-tuning rather than thematic shifts [7] - Humana (HUM) remains a significant healthcare position at $1.05 billion (3.39%), with a slight reduction [7] Full Exits - The quarter saw complete disposals of smaller positions including Shyft Group (SHYF), Synovus Financial (SNV), NatWest Group (NWG), ICICI Bank (IBN), Ulta Beauty (ULTA), and Alkermes (ALK S), reflecting a consolidation towards higher-conviction U.S. large-caps [8] Outlook - Pzena's Q3 2025 update highlights its status as a deep-value investor in a growth-focused market, with significant additions to Baxter and stable positions in Magna and Citigroup, emphasizing a commitment to low-multiple, high-cash-flow companies [9]

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious malfunctions and patient risks [3][4]. Summary by Sections Allegations - The complaint claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were characterized as materially false and misleading [3]. Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to July 30, 2025 [3]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [6]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP, and that their remedial measures were inadequate [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [5]. - The firm has been recognized for its performance in the field, being ranked highly for the number of securities class action settlements [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. to recover losses incurred by shareholders due to alleged securities fraud between February 23, 2022, and July 30, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit alleges that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is claimed that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were allegedly materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

Summary of Baxter International Conference Call Company Overview - **Company**: Baxter International (NYSE:BAX) - **Date**: November 18, 2025 - **Key Speakers**: Joel Grade (CFO), Kevin Moran (Investor Relations) Key Points Industry and Company Changes - Baxter has undergone significant portfolio management, divesting non-core businesses to focus on core operations [3][4] - The acquisition of Hillrom in December 2021 led to increased debt and integration challenges, prompting strategic changes in January 2023 [4][5] - Key divestitures included the BPS (contract manufacturing) and kidney businesses, aimed at debt reduction and strategic alignment [4][5] Financial Performance and Growth Strategy - The company aims to stabilize operations and improve cash generation for reinvestment in growth [6][8] - Baxter's current focus is on enhancing operational consistency and predictability, with no major portfolio changes anticipated in the near term [6][8] - The advanced surgery business within the MPT segment grew by 11% last quarter, indicating strong performance [11] Segment Performance - **MPT Segment**: - Challenges with the Novum pump, but the Spectrum pump remains a strong alternative [9][10] - Fluid conservation efforts have reset the baseline for growth, with expectations for continued growth in this area [10][26] - **HST Segment**: - Positive order book with a 30% increase year-over-year, indicating strong demand [11] - Anticipated modest growth in frontline care markets [12] - **Pharmaceutical Segment**: - Compounding is a fast-growing area, although it has lower margins [12] - Anesthesia business showed high single-digit growth, but challenges remain in the U.S. injectables market due to market shifts [12][13] Future Outlook - Baxter plans to provide more detailed guidance and a long-range plan update in 2026 [14] - The company is focused on new product launches, including the Connex 360 monitor, which is expected to enhance margins in the future [16][17] - Ongoing efforts to improve margins through cost efficiencies and product mix optimization [18] Regulatory and Market Challenges - The Novum pump's market re-entry is uncertain, with expectations that it may extend beyond 2025 [21][22] - Baxter is actively engaging with regulators to ensure compliance and safety during the Novum pump's return process [22] - The company is managing tariff impacts, with a net impact of approximately $40 million, and is focusing on targeted pricing actions to mitigate these effects [32][34] GPO Contracts and Pricing Strategy - Baxter renegotiated two of three large GPO contracts, resulting in an anticipated 100 basis points price increase at the enterprise level [30] - The third GPO contract will be renegotiated in late 2026, impacting 2027 pricing [31] Conclusion - Baxter is navigating a complex landscape of operational challenges and market dynamics while focusing on core business growth and strategic realignment. The company is committed to enhancing its product offerings and operational efficiencies to drive future growth and profitability [40]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]